Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10 111â122. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Dovepress
open access to scientific and medical research
ORIGINAL RESEARCH
Open Access Full Text Article
Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials This article was published in the following Dove Press journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 29 March 2017 Number of times this article has been viewed
Michelle E Orme 1 Hiep Nguyen 2 Jackie Y Lu 3 Susan A Thomas 3 ICERA Consulting Ltd, Swindon, UK; AstraZeneca, Wilmington, DE, 3 AstraZeneca, Fort Washington, PA, USA 1 2
Background: Clinical studies of patients with type 2 diabetes show that GLP-1 receptor agonists (GLP-1 RAs) improve glycemic control and promote weight loss. We conducted a Bayesian network meta-analysis (NMA) of placebo- and active-controlled randomized trials to assess the comparative effectiveness of liraglutide, albiglutide, dulaglutide, and exenatide twice daily and once weekly, with a focus on glycemic control. Materials and methods: We searched Medline, Embase, and the Cochrane Library (up to December 2014) for core registration programs for US-approved GLP-1 RAs. Patients reaching an A1C target of
